Compugen SVP exercises options, sells 2,000 shares
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,000 shares ($4K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Levine Zurit
Role
SVP, Business Development
Sold
2,000 shs ($6K)
Approx. gross sale proceeds
$6K
Approx. exercise cost
$2K
Approx. pre-tax spread
$4K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (right to buy) | 2,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 2,000 | $1.15 | $2K |
| Sale | Ordinary Shares | 2,000 | $3.20 | $6K |
Holdings After Transaction:
Share Option (right to buy) — 52,000 contracts (Direct);
Ordinary Shares — 29,375 shares (Direct)
Footnotes (2)
- F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.
- F2. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
Key Figures
Shares sold: 2,000 shares
Sale price: $3.20 per share
Options exercised: 2,000 shares
+4 more
7 metrics
Shares sold
2,000 shares
Ordinary Shares sold at $3.20 on April 24, 2026
Sale price
$3.20 per share
Open-market sale of 2,000 Ordinary Shares
Options exercised
2,000 shares
Exercise of options into Ordinary Shares
Exercise price
$1.15 per share
Share Option (right to buy) conversion price
Post-transaction holdings
29,375 shares
Ordinary Shares directly owned after transactions
Trading plan adoption date
December 23, 2025
Rule 10b5-1 trading plan for reported sale
Option expiration
August 3, 2033
Expiration date for exercised Share Option grant
Key Terms
Rule 10b5-1 trading plan, Share Option (right to buy), derivative security, open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale" for the 2,000 Ordinary Shares"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Compugen (CGEN) SVP Zurit Levine report?
Zurit Levine reported exercising options for 2,000 ordinary shares and selling 2,000 ordinary shares. The sale was an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, providing structure and automation to the trading activity.
What options did the Compugen (CGEN) SVP exercise in this Form 4?
Levine exercised options to acquire 2,000 ordinary shares at an exercise price of $1.15 per share. These options were part of a grant that vested 25% on September 30, 2024, with the remainder vesting in 12 equal quarterly installments, subject to continued service.
Was the Compugen (CGEN) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Zurit Levine on December 23, 2025. Such plans allow insiders to schedule trades in advance according to predefined instructions and timing.
What are the vesting terms of the Compugen (CGEN) option exercised by the SVP?
The option exercised vested 25% on September 30, 2024. The remaining portion vested or vests in 12 equal quarterly installments thereafter, conditioned on the SVP’s continued service to Compugen, as described in the footnote to the insider transaction disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
